To study the function of ␥-glutamyl leukotrienase (GGL), a newly identified member of the ␥-glutamyl transpeptidase (GGT) family, we generated null mutations in GGL (GGL tm1 ) and in both GGL and GGT (GGL tm1 -GGT tm1 ) by a serial targeting strategy using embryonic stem cells. Mice homozygous for GGL tm1 show no obvious phenotypic changes. Mice deficient in both GGT and GGL have a phenotype similar to the GGT-deficient mice, but ϳ70% of these mice die before 4 weeks of age, at least 2 months earlier than mice deficient only in GGT. These double-mutant mice are unable to cleave leukotriene C 4 (LTC 4 ) to LTD 4 , indicating that this conversion is completely dependent on the two enzymes, and in some organs (spleen and uterus) deletion of GGL alone abolished more than 90% of this activity. In an experimental model of peritonitis, GGL alone is responsible for the generation of peritoneal LTD 4 . Further, during the development of peritonitis, GGL-deficient mice show an attenuation in neutrophil recruitment but not of plasma protein influx. These findings demonstrate an important role for GGL in the inflammatory response and suggest that LTC 4 and LTD 4 have distinctly different functions in the inflammatory process.Leukotrienes (LT) are a group of biologically active metabolites of arachidonic acid and have been implicated in the pathophysiology of many inflammatory diseases, including asthma, arthritis, psoriasis, and inflammatory bowel disease (8,17,20). Unlike many other inflammatory mediators, LT are not stored but synthesized de novo in response to inflammatory stimuli (17). Synthesis of LT is an intracellular process initiated by the conversion of free arachidonic acid to LTA 4 , an epoxide intermediate, by the key enzyme 5-lipoxygenase and the accessory protein 5-lipoxygenase-activating protein. LTA 4 can be converted to LTB 4 by LTA 4 hydrolase or conjugated with glutathione (GSH) by LTC 4 synthase to form LTC 4 . LTC 4 is then transported to the extracellular microenvironment where it is converted to LTD 4 (the cysteinyl glycine conjugate of LTA 4 ) and then to LTE 4 (the cysteinyl conjugate of LTA 4 ).LTC 4 and its metabolites, LTD 4 and LTE 4 , are referred to as cysteinyl LT and were originally identified as the active components of the slow reacting substance of anaphylaxis. They are known to stimulate a wide spectrum of inflammatory processes, including vasoconstriction, increases in postcapillary venule permeability, local recruitment of eosinophils, bronchoconstriction, and mucous secretion (8,9,17,19,20). LT have been the focus of extensive investigation in recent years because of the potency of their inflammatory effects, particularly in asthma, and promising therapeutic results with novel inhibitors of their synthesis and/or antagonists of their receptors (9,19).Cysteinyl LT exert their effects through specific receptors;however, there has been significant uncertainty about the interaction of cysteinyl LT with their receptors and the relative potencies of individual cysteinyl LT. In vivo studies...